Title Treatment # Of subjects Methods Inclusion criteria Major outcome(s) Results of major outcome(s) Reference Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate AD Rosi 2mg, Rosi 4mg, Rosi 8mg, or placebo daily for 24 weeks 511 RCT Probable AD, MMSE score of 16-26 ADAS-Cog and CIBIC+ No significant difference; exploratory analyses suggested that ApoE4 non-carriers exhibited cognitive improvement with 8mg dose of Rosi [35 ] Rosiglitazone monotherapy in mild-to-moderate AD: results from a randomized, double-blind, placebo-controlled phase III study. Rosi XR 2mg, Rosi XR 8 mg, donepezil 10mg, or placebo daiy for 24 weeks 693 RCT Probable AD, MMSE score of 10-23 ADAS-Cog and CIBIC+ No significant difference for Rosi group vs. placebo; no interaction between treatment and ApoE status [36 ] Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate AD: two phase 3 studies. Rosi XR 2mg, Rosi XR 8 mg, or placebo daily for 48 weeks in addition to an AChEI 2,822 RCT Mild-moderate probable AD, MMSE score of 10-26 ADAS-Cog and CDR-SB No significant difference; no interaction between treatment and ApoE status [37 ] Efficacy of PPAR- agonist pioglitazone in mild AD Pio 15-30 mg daily or no treatment for 6 months 42 randomized, open-label Mild AD, Clinical Dementia Rating score of 0.5 or 1 MMSE, ADAS-Cog Significant improvement in MMSE and ADAS-cog from baseline in pio treated subjects [38 ] Biomarker Qualification for Risk of MCI Due to AD and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW) Pio 0.8mg SR daily or placebo for up to 5 years 3,494 RCT Cognitively normal patients Time to diagnosis of MCI due to AD for subjects in the high-risk stratum Trial discontinued due to inadequate treatment effect; full results not yet published [39 ] Telmisartan vs. Perindopril in Hypertensive Mild-Moderate AD Patients (SARTAN-AD) Telmi 40mg, Telmi 80mg, perindopril 2mg, perindopril 4mg, or perindopril 8mg daily for 12 months goal of 240 Randomized, open label Probable AD or possible AD dementia due to concomitant cerebrovascular disease, MMSE 16-27 Ventricular enlargement, cognitive function based on ADAS-cog and cognitive battery Trial is ongoing [40 ] Effects of telmisartan on the level of A 1-42, interleukin-1 , TNF and cognition in hypertensive patients with AD Telmi 40-80mg or amlodipine 5-10 mg daily for 6 months 48 Randomized Probable AD and essential hypertension ADAS-Cog and MMSE Significant improvement in MMSE and ADAS-cog in Telmi treated subjects compared to amlodipine treated subjects [41 ] Phase 2a Feasibility Study of T3D-959 in Subjects with Mild to Moderate AD T3D-959 36 Randomized, open-label Mild-to-moderate AD, MMSE score of 14 -26 FDG-PET Imaging, ADAS-Cog Trends towards improvement in ADAS-Cog [42 ]
